Duloxetine Capsule, Delayed Release
Product Images NDC 71335-3062

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-3062). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

This text appears to be a data table showing the number of patients experiencing a relapse over time in a study comparing a placebo with the drug Duloxetine. The x-axis indicates the time from randomization to relapse in days, while the y-axis lists the number of patients with relapse. The data presented could help evaluate the effectiveness of Duloxetine in preventing relapse compared to a placebo.*

FDA Label Image

Figure10 (Duloxetine Fig10)

This is a description of a medication regimen involving Duloxetine at a dose of 60/120 mg once daily compared to a placebo. The text also indicates the calculation of percent improvement in pain from baseline using BOCF method. The specific details about the study or context are not available.*

FDA Label Image

Figure2 (Duloxetine Fig2)

This graph shows the proportion of patients experiencing a relapse over time following randomization into treatment with either a placebo or duloxetine. The x-axis represents the time in days from randomization to relapse, while the y-axis depicts the proportion of patients experiencing relapse. The graph presents data points for both the placebo and duloxetine treatment groups, showing how the proportion of patients with relapse changes over time.*

FDA Label Image

Figure3 (Duloxetine Fig3)

FDA Label Image

Figure4 (Duloxetine Fig4)

FDA Label Image

Figure5 (Duloxetine Fig5)

This text mentions the percentage of patients improved with different medication dosages of Duloxetine and a placebo in relation to the percentage improvement in pain from baseline. It seems to be a comparison chart showing the effectiveness of different treatment options in pain management.*

FDA Label Image

Figure6 (Duloxetine Fig6)

FDA Label Image

Figure7 (Duloxetine Fig7)

This text shows a chart indicating the percentages of patients improved with Duloxetine 60 mg once daily compared to placebo in terms of pain improvement from baseline. The chart displays values ranging from 0 to 100 percent.*

FDA Label Image

Figure8 (Duloxetine Fig8)

This text appears to be showing information about the administration of duloxetine at doses of 60mg to 120mg once daily for placebo group. Additionally, there is mention of percent improvement in pain from baseline.*

FDA Label Image

Figure9 (Duloxetine Fig9)

This text provides information about a medication study comparing placebo versus duloxetine 60 mg taken once daily. The document includes details of pain improvement percentages from baseline over the course of the study period.*

FDA Label Image

Structure (Duloxetine Structure)

FDA Label Image

Label (Lbl713353062)

This is a package insert for Duloxetine Delayed-Release Capsules, USP containing 22.4 mg of Duloxetine Hydrochloride equivalent to 20 mg Duloxetine per capsule. It provides storage recommendations, dosage information, and instructs pharmacists to dispense a Medication Guide to each patient. The capsules are repackaged by Bryant Ranch Prepack, Inc. in Burbank, CA, and manufactured by Ajanta Pharma Limited. The NDC code for the product is 71335-3062-1.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.